Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 10.1B 8.82B 8.16B 7.62B 14.3B 954B 14.4B 96.97B 37.73B 469B 37.91B 37.08B 1,630B P/E 2026 *
23.5x
P/E 2027 * 18.3x
Enterprise Value 10.18B 8.89B 8.23B 7.68B 14.41B 962B 14.52B 97.74B 38.03B 473B 38.21B 37.38B 1,643B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.49x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day-4.70%
1 week-6.23%
Current month-4.16%
1 month-10.30%
3 months-38.83%
6 months-52.36%
Current year-51.13%
1 week 138.84
Extreme 138.84
150.89
1 month 138.84
Extreme 138.84
161.35
Current year 138.84
Extreme 138.84
299.8
1 year 138.84
Extreme 138.84
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
06-02Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%-6.23%-54.85%-52.33% 10.1B
-0.07%-1.08%-34.18%-18.97% 154B
-0.08%-1.57%-7.96%-9.48% 102B
-0.99%+2.10%+59.76%+56.65% 56.51B
+3.84%-3.69%-7.53%+44.28% 52.89B
-1.99%-3.67%-17.41%-45.68% 39.67B
+1.18%-7.03% - - 30.39B
-4.79%-6.99%-13.53%-45.44% 27.96B
-0.09%-0.57%+52.08%-10.61% 23.17B
+0.90%+2.05%-14.45%-4.79% 20.35B
Average -1.50%-1.75%-4.23%-9.60% 51.66B
Weighted average by Cap. -0.82%-1.64%-7.82%-4.72%

Financials

2026 *2027 *
Net sales 3.32B 2.9B 2.69B 2.51B 4.71B 314B 4.74B 31.92B 12.42B 154B 12.48B 12.21B 536B 3.94B 3.44B 3.18B 2.97B 5.58B 372B 5.62B 37.81B 14.71B 183B 14.78B 14.46B 635B
Net income 432M 378M 349M 326M 612M 40.83B 616M 4.15B 1.61B 20.08B 1.62B 1.59B 69.74B 565M 494M 457M 426M 800M 53.4B 806M 5.43B 2.11B 26.26B 2.12B 2.08B 91.21B
Net Debt 80.64M 70.46M 65.17M 60.83M 114M 7.62B 115M 774M 301M 3.75B 303M 296M 13.02B -289M -252M -233M -218M -409M -27.29B -412M -2.77B -1.08B -13.42B -1.08B -1.06B -46.61B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-06-22 138.89 $ -4.71% 1,009,597
26-06-18 145.76 $ +1.56% 2,864,144
26-06-17 143.52 $ -2.82% 1,542,221
26-06-16 147.69 $ -0.30% 942,276
26-06-15 148.14 $ -1.04% 1,041,258
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
145.76USD
Average target price
242.43USD
Spread / Average Target
+66.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!